Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie

Clémence Basse, Claire Morel, Marie Alt, Marie Paule Sablin, Coralie Franck, Gaëlle Pierron, Céline Callens, Samia Melaabi, Julien Masliah-Planchon, Guillaume Bataillon, Sophie Gardrat, Marion Lavigne, Benjamin Bonsang, Pauline Vaflard, Elvire Pons Tostivint, Coraline Dubot, Delphine Loirat, Miguelle Marous, Romain Geiss, Nathalie Clément, Gudrun Schleiermacher, Choumouss Kamoun, Elodie Girard, Maude Ardin, Camille Benoist, Virginie Bernard, Odette Mariani, Roman Rouzier, Patricia Tresca, Vincent Servois, Anne Vincent-Salomon, Ivan Bieche, Christophe Le Tourneau, Maud Kamal